Diplomat Pharmacy (DPLO) Tops Q4 EPS by 2c; Issues Strong FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts DPLO Hot Sheet
Join SI Premium – FREE
Diplomat Pharmacy (NYSE: DPLO) reported Q4 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $612 million versus the consensus estimate of $603.7 million.
Diplomat Pharmacy sees FY2015 EPS of $0.47-$0.50, versus the consensus of $0.42.
For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
- Kotak Mahindra Bank Ltd. (KMB:IN) PT Raised to INR492 at JPMorgan
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
